Adam Walsh
Stock Analyst at Roth Capital
(2.48)
# 2,269
Out of 5,129 analysts
14
Total ratings
58.33%
Success rate
13.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Initiates: Buy | $212 | $148.43 | +42.83% | 1 | Jan 23, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $58 | $34.46 | +68.31% | 1 | Jan 23, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $171 | $221.49 | -22.80% | 3 | Apr 20, 2020 | |
| GLPG Galapagos NV | Maintains: Buy | $121 → $188 | $34.09 | +451.48% | 4 | Jul 15, 2019 | |
| CORT Corcept Therapeutics | Downgrades: Hold | n/a | $40.83 | - | 4 | May 31, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $74 → $77 | $23.88 | +222.45% | 1 | Apr 18, 2018 |
Insmed
Jan 23, 2026
Initiates: Buy
Price Target: $212
Current: $148.43
Upside: +42.83%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $34.46
Upside: +68.31%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146 → $171
Current: $221.49
Upside: -22.80%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121 → $188
Current: $34.09
Upside: +451.48%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $40.83
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74 → $77
Current: $23.88
Upside: +222.45%